Introduction:
A seizure is defined clinically as a paroxysmal alteration in neurological function i.e., motor, behavioral and/or autonomic function. 1 The prevalence of seizure is 1-3/1000 live births in term and 10-15/1000 in preterm deliveries. 2 The common cause of neonatal seizures arehypoxic ischemic encephalopathy (HIE), Metabolic causes (hypoglycaemia, hypocalaemia, hypomagnesaemia, etc), Infection (Meningitis, viral encephalitis etc), intracranial haemorrhage, Cerebral infarcts, Developmental brain defects, drug withdrawal, drug toxicity. [1] [2] [3] Intractable seizure are defined when seizure events don't respond to first line treatment of an intravenous bolus of injection Phenobarbital (20 mg/kg) and up to 2 loading doses of (10 mg/ kg) Phenobarbital 4 (maximum 40 mg/kg). There is no available data about the prevalence of intractable seizure both globally and nationally.
Treatment options for neonatal seizures remain limited despite their relatively common occurrence even with introduction of several new antiepileptic medications over the past two decades. In addition there is significant variation in approach to the treatment of intractable neonatal seizure both in medication choice and in when, or whether to treat.
At present Phenobarbital and phenytoin is treatment of choice as 1 st and 2 nd line drugs in neonatal seizure. Laurel et al. 5 study show the efficacy is only approximately 50% of Phenobarbital and phenytoin in neonatal seizure. Phenytoin was shown to only provide about a 10% to increase in intractable seizure control when given following Phenobarbital failure 5 . In addition phenytoin impairs myocardial function and can cause hypotension or arrhythmia in neonate. Federico et al 6 observed clinical side effects such as drowsiness, sleep troubles, hyperactivity, movement disorders in 43.6% cases treated with Inj. Phenytoin.
Lidocaine is effective drug and has been widely used in treatments of neonatal seizures without any severe side effects. It is an effective drug for second-or third-line treatment of neonatal seizures not responding to traditional anticonvulsant therapy 7, 8, 9 Since 1955 it has been used as an anticonvulsant drugs in adults with status epilepticus. 10 It has been used in neonates as an anticonvulsant since 1970. 10 It may have following side effects such as drowsiness, convulsion in higher dose, respiratory depression, cardiovascular collapse, bradycardia. 11 However, the efficacy of lidocaine for intractable neonatal seizure in neonates has not been adequately studied. So this study is intended to see the efficacy and side effects of lidocaine which may open a new horizon of management of intractable neonatal seizure. Maintenance were given 4mg/kg/ hour for first 12 hours then followed by 2mg/ kg/hr for next 12 hours in IV drip for lidocaine group and 7.5mg/kg/day for twelve hours lives for phenytoin group. If convulsion occured during maintenance therapy of lidocaine or not responding to both lidocaine and fosphenytoin then Inj. midazolom was given in both groups. The patients were followed up regularly till death or discharge.
Methodology

Results :
The present randomized controlled trial was intended to compare the outcome of two treatment modalities [inj.
The findings obtained from data analyses are documented below: Table I shows basic demographic data of the neonates with intractable seizure. Out of 32 neonates in group A and 35 neonates in group B, respectively, 20 (62.5%) and 22 (62.9%) were male and 12 (37.5%) and 13 (37.1%) were female. The sex distribution of neonates between group was statistically not significant. 16 Lidocaine has a harrow therapeutic range and can induce seizure in high dose. 17 Time required to control seizure is nearly similar in both groups. In lidocaine group 75% of patients responded within 24 hours. On the other hand 71% of patients responded in same duration in phenytoin group. Lidocaine is considered to be effective only when convulsion are controlled for 24 hours. 17 Boylan et al 14 shows 60% of neonates responded to lidocaine after failure of phenobarbitone& took more than 12 hours. Cessation of seizure activity 6 hours or longer is seen in 77% of patients and was considered a good response. 4 HellostromWestas shows the 83% of patients responds to lidocaine within 12 hours 8 . Lidocaine led to seizure termination of neonatal seizure in 63% of term infants when administrated as second line treatment for neonatal seizure within 24 hours. 18 In the present study, length of hospital stay is less in phenytoin group (7 patients in 5 days) in comparable to lidocaine group (2 in 5 days). But this findings could not signify efficacy of the drugs. As death (total 20%), left against medical advice (14.3%) is more in phenytoin group than in lidocaine group (death 12.5%, left against medical advice 9.4%).
In summary for controlling intractable neonatal seizures Inj. Lidocaine group showed more efficacious than Inj. phenytoin group and causing less adverse effects. Though it is not statistically significant.
Conclusion:
Inj. Lidocaine is similar to Inj. Phenytoin in controlling intractable neonatal seizure. But large sample, multi centre randomized trial needed to validate the effect of lidocaine in controlling intractable seizure.
